secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001493152-26-001170
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir receives Nasdaq non-compliance notice for missing annual meeting; has until Feb 23 to submit plan
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 8, 2026 for failure to hold annual meeting within 12 months of fiscal year end (Rule 5620(a)).
- No immediate delisting; trading continues. Must submit compliance plan by Feb 23, 2026.
- Preliminary proxy filed Nov 20, 2025 still under SEC review; expects to hold meeting promptly after clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226001170/0001493152-26-001170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226001170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-001170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer